X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ACTAVIS (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   ACTAVIS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
ACTAVIS
Dec-14
DR. REDDYS LAB/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs2,78819,470-   
Low Rs1,90211,876-   
Sales per share (Unadj.) Rs860.83,506.0-  
Earnings per share (Unadj.) Rs57.1-437.5-  
Cash flow per share (Unadj.) Rs122.0321.7-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.77,604.3-  
Shares outstanding (eoy) m165.91265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.5 60.9%   
Avg P/E ratio x41.1-35.8 -114.7%  
P/CF ratio (eoy) x19.248.7 39.4%  
Price / Book Value ratio x3.12.1 150.1%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0344,167,411 9.3%   
No. of employees `00023.521.6 108.9%   
Total wages/salary Rs m32,1490-   
Avg. sales/employee Rs Th6,070.843,159.0 14.1%   
Avg. wages/employee Rs Th1,366.60-   
Avg. net profit/employee Rs Th402.5-5,385.8 -7.5%   
INCOME DATA
Net Sales Rs m142,810932,235 15.3%  
Other income Rs m1,552-2,327 -66.7%   
Total revenues Rs m144,362929,908 15.5%   
Gross profit Rs m23,512119,759 19.6%  
Depreciation Rs m10,772201,863 5.3%   
Interest Rs m78829,404 2.7%   
Profit before tax Rs m13,504-113,835 -11.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m0-8,350 0.0%   
Tax Rs m4,380-5,852 -74.8%   
Profit after tax Rs m9,468-116,333 -8.1%  
Gross profit margin %16.512.8 128.2%  
Effective tax rate %32.45.1 630.9%   
Net profit margin %6.6-12.5 -53.1%  
BALANCE SHEET DATA
Current assets Rs m104,984491,168 21.4%   
Current liabilities Rs m68,938358,206 19.2%   
Net working cap to sales %25.214.3 177.0%  
Current ratio x1.51.4 111.1%  
Inventory Days Days7458 128.2%  
Debtors Days Days10466 156.3%  
Net fixed assets Rs m104,385113,835 91.7%   
Share capital Rs m8300-   
"Free" reserves Rs m124,8860-   
Net worth Rs m125,7162,021,983 6.2%   
Long term debt Rs m25,0891,059,559 2.4%   
Total assets Rs m225,4433,705,630 6.1%  
Interest coverage x18.1-2.9 -631.7%   
Debt to equity ratio x0.20.5 38.1%  
Sales to assets ratio x0.60.3 251.8%   
Return on assets %4.5-2.3 -193.9%  
Return on equity %7.5-5.8 -130.9%  
Return on capital %9.7-3.0 -322.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m53,7070-   
CASH FLOW
From Operations Rs m18,030160,083 11.3%  
From Investments Rs m-14,883-383,300 3.9%  
From Financial Activity Rs m-4,440215,359 -2.1%  
Net Cashflow Rs m-1,236-7,858 15.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare DR. REDDYS LAB With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: PLETHICO PHARMA  LUPIN LTD  FULFORD INDIA  ORCHID PHARMA LTD  TORRENT PHARMA  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 20, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS